The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants
- Authors
- Lee, Ji Yun; Oh, Il-Young; Lee, Ju-Hyeon; Kim, Sang-Young; Kwon, Seong Soon; Yang, Hyeon-Jong; Kim, Yang-Ki; Bang, Soo-Mee
- Issue Date
- Nov-2020
- Publisher
- Pergamon Press
- Keywords
- Direct oral anticoagulant; Drug-drug interaction; Bleeding; Atrial fibrillation; Venous thromboembolism
- Citation
- Thrombosis Research, v.195, pp 243 - 249
- Pages
- 7
- Journal Title
- Thrombosis Research
- Volume
- 195
- Start Page
- 243
- End Page
- 249
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2368
- DOI
- 10.1016/j.thromres.2020.07.054
- ISSN
- 0049-3848
- Abstract
- Introduction: Direct oral anticoagulants (DOACs) have the potential to increase bleeding due to drug-drug interactions (DDIs). In the present study, the risk of bleeding was evaluated when drugs with potential DDIs were simultaneously prescribed with DOACs. Materials and methods: The present study included patients with non-valvular atrial fibrillation (AF) and venous thromboembolism (VTE) who were newly prescribed DOACs between January 2014 and December 2016. Results: The study included 115,362 patients with AF or VTE who were newly administered DOACs (median age, 73 years, range, 19-108 years; males, 53.0%; AF, 81.9%). A total of 7001 any bleeding (6.1%) and 2283 major bleeding (2.0%) events occurred with DOAC prescriptions. Based on multiple logistic regression analysis, the number of DDIs was significantly associated with bleeding events independent of CHA2DS2-VASc score and Charlson Comorbidity Index (CCI). The rates of exposure to DDI drugs associated with any bleeding and major bleeding were 56.7% and 66.1%, respectively. The most common DDI drugs showed similar distributions in any or major bleeding; non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, diltiazem, and amiodarone were frequently prescribed. Conclusions: Physicians prescribing DOACs for AF or VTE should be aware of the increasing risk of bleeding associated with drugs having potential DDIs regardless of comorbidities.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of Pediatrics > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2368)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.